查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1947840

PET放射性追蹤劑市場分析及預測（至2035年）：類型、產品、服務、技術、應用、最終用戶、組件、部署、流程、設備

PET Radiotracer Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Component, Deployment, Process, Equipment
出版日期: | 出版商: Global Insight Services | 英文 342 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

預計PET放射性示蹤劑市場將從2024年的26億美元成長到2034年的65億美元，複合年成長率約為7%。 PET放射性追蹤劑市場涵蓋正子斷層掃描（PET）影像中使用的放射性追蹤劑的開發、生產和分銷。這些放射性追蹤劑在診斷和後續觀察包括癌症和神經系統疾病在內的多種疾病方面至關重要。放射化學的進步、慢性病的增加以及對精準醫療日益成長的需求是推動市場成長的主要因素。示踪劑設計的創新以及對新型成像劑的監管支持進一步促進了市場成長，凸顯了研發領域的投資機會。

PET放射性追蹤劑市場正經歷強勁成長，主要得益於診斷影像技術和腫瘤學研究的進步。腫瘤學領域在表現方面處於主導地位，FDG和PSMA等示蹤劑在癌症檢測和治療中展現出卓越的療效。心臟病學是第二大成長領域，主要由銣-82等示蹤劑驅動，銣-82是心肌灌注影像的關鍵示蹤劑。神經病學應用也呈現成長勢頭，特別是靶向澱粉樣蛋白和Tau蛋白的示踪劑，用於阿茲海默症診斷。對更精準、更個人化的診斷解決方案的需求不斷成長，推動了新型放射性示蹤劑的需求。放射化學的創新和靶向示踪劑的開發正在提高診斷準確性和改善患者預後。此外，PET影像與其他影像方式（如CT和MRI）的結合正在擴大其臨床應用範圍。製藥公司和研究機構之間的策略合作正在推動下一代放射性示蹤劑的研發，預計將在這個不斷發展的市場中帶來盈利的機會。

市場區隔
類型 氟代脫氧葡萄糖（FDG）、鎵-68、碳-11、氮-13、氧-15、銅-64、鋯-89、碘-124
產品 腫瘤放射性示蹤劑、心臟病放射性示蹤劑、神經學放射性示蹤劑
服務 放射性示蹤劑生產、放射性示蹤劑分發、放射性示蹤劑研發
科技 迴旋加速器，發電機底座
應用領域 腫瘤科、心臟科、神經科、感染疾病影像科、檢查科
最終用戶 醫院、診斷中心、研究機構、製藥公司
成分 放射性同位素、放射性藥物
實施表格 內部生產，外包生產
流程 合成、品管、包裝、分銷
裝置 PET掃描器、迴旋加速器、熱室

PET放射性追蹤劑市場的特徵是市場佔有率和定價策略的動態變化。主要企業正致力於推出創新產品以鞏固其市場地位。定價策略受生產複雜性和對先進影像診斷解決方案的需求影響。新產品的推出正在提升診斷能力，以滿足日益成長的精準醫療需求。市場正經歷個人化醫療的趨勢，推動著新型放射性示蹤劑的應用。 PET放射性追蹤劑市場競爭激烈，主要企業都在追求技術優勢。基準分析表明，擁有強大的研發開發平臺和策略聯盟的企業具有競爭優勢。法規結構，尤其是在北美和歐洲，對塑造市場動態至關重要。這些法規確保了產品的安全性和有效性，並影響企業的市場進入和擴大策略。分子成像技術的進步以及對疾病早期檢測日益成長的關注正在推動市場成長。挑戰包括監管合規成本和持續創新的需求。

主要趨勢和促進因素：

PET放射性追蹤劑市場正經歷蓬勃發展，這主要得益於醫學影像技術的進步和慢性病發病率的上升。其中一個關鍵趨勢是將人工智慧（AI）融入診斷成像，從而提高診斷的準確性和效率。隨著醫療機構追求精準醫療，這項技術革新正推動市場需求。此外，全球對疾病早期檢測（尤其是在腫瘤領域）的日益重視也顯著推動了市場成長。患者和醫療系統越來越重視早期療育，從而提高了PET放射性示蹤劑的應用率。另一個促進因素是老年人口的成長，老年人更容易罹患癌症和阿茲海默症疾病，這進一步增加了對先進診斷影像解決方案的需求。此外，製藥公司與研究機構之間的合作正在促進創新，並推動新型放射性示蹤劑的研發。這些合作對於滿足未被滿足的臨床需求和拓展PET放射性示蹤劑的應用範圍至關重要。最後，監管機構對核子醫學研究的支持和資金投入也在推動市場擴張，尤其是在那些注重醫療基礎建設的地區。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 氟代脫氧葡萄糖（FDG）
    • 鎵-68
    • 碳-11
    • 氮-13
    • 氧-15
    • 銅-64
    • 鋯-89
    • 碘-124
  • 市場規模及預測：依產品分類
    • 腫瘤放射性示蹤劑
    • 心臟病學放射性示蹤劑
    • 神經放射性示踪劑
  • 市場規模及預測：依服務分類
    • 放射性示踪劑的生產
    • 放射性示蹤劑分佈
    • 放射性示蹤劑的研究與開發
  • 市場規模及預測：依技術分類
    • 迴旋加速器
    • 發電機基座
  • 市場規模及預測：依應用領域分類
    • 腫瘤學
    • 心臟病學
    • 神經病學
    • 感染影像
    • 研究
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 診斷中心
    • 研究所
    • 製藥公司
  • 市場規模及預測：依組件分類
    • 放射性同位素
    • 放射性藥物
  • 市場規模及預測：依發展狀況
    • 內部生產
    • 外包生產
  • 市場規模及預測：依製程分類
    • 合成
    • 品管
    • 包裝
    • 分配
  • 市場規模及預測：依設備分類
    • PET掃描儀
    • 迴旋加速器
    • 熱賣商品

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 其他亞太地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章 公司簡介

  • Advanced Accelerator Applications
  • Blue Earth Diagnostics
  • Jubilant Radiopharma
  • Curium Pharma
  • SOFIE Biosciences
  • North Star Medical Radioisotopes
  • Zevacor Molecular
  • ABX-CRO
  • Cyclomedica
  • ITG Isotope Technologies Garching
  • Radiopharm Theranostics
  • ARTMS Products
  • Telix Pharmaceuticals
  • Global Medical Solutions
  • Imagin Ab
  • Eckert & Ziegler Radiopharma
  • Shine Medical Technologies
  • Lantheus Holdings
  • Isotopia Molecular Imaging
  • TRIUMF Innovations

第9章：關於我們

簡介目錄
Product Code: GIS26303

PET Radiotracer Market is anticipated to expand from $2.6 billion in 2024 to $6.5 billion by 2034, growing at a CAGR of approximately 7%. The PET Radiotracer Market encompasses the development, production, and distribution of radiotracers used in positron emission tomography (PET) imaging. These radiotracers are critical for diagnosing and monitoring various diseases, including cancer and neurological disorders. The market is driven by advancements in radiochemistry, increasing prevalence of chronic diseases, and growing demand for precision medicine. Innovations in tracer design and regulatory support for novel imaging agents further propel market growth, highlighting opportunities for investment in research and development.

The PET Radiotracer Market is experiencing robust growth, primarily fueled by advancements in diagnostic imaging and oncology research. The oncology segment leads in performance, with tracers such as FDG and PSMA demonstrating significant efficacy in cancer detection and management. Cardiology follows as the second highest-performing segment, driven by tracers like Rubidium-82, which are crucial for myocardial perfusion imaging. Neurology applications are also gaining momentum, particularly with tracers targeting amyloid and tau proteins for Alzheimer's diagnosis. The demand for novel radiotracers is rising, spurred by the need for more precise and personalized diagnostic solutions. Innovations in radiochemistry and the development of targeted tracers are enhancing diagnostic accuracy and patient outcomes. Additionally, the integration of PET imaging with other modalities, such as CT and MRI, is expanding clinical applications. Strategic collaborations between pharmaceutical companies and research institutions are fostering the development of next-generation radiotracers, promising lucrative opportunities in this evolving market.

Market Segmentation
TypeFluorodeoxyglucose (FDG), Gallium-68, Carbon-11, Nitrogen-13, Oxygen-15, Copper-64, Zirconium-89, Iodine-124
ProductOncology Radiotracers, Cardiology Radiotracers, Neurology Radiotracers
ServicesRadiotracer Production, Radiotracer Distribution, Radiotracer Research and Development
TechnologyCyclotron, Generator-based
ApplicationOncology, Cardiology, Neurology, Infection Imaging, Research
End UserHospitals, Diagnostic Centers, Research Institutes, Pharmaceutical Companies
ComponentRadioisotopes, Radiopharmaceuticals
DeploymentIn-house Production, Outsourced Production
ProcessSynthesis, Quality Control, Packaging, Distribution
EquipmentPET Scanners, Cyclotrons, Hot Cells

The PET Radiotracer Market is characterized by a dynamic landscape of market share and pricing strategies. Leading companies are focusing on innovative product launches to strengthen their market positions. The pricing strategies are influenced by the complexity of production and the demand for advanced imaging solutions. New product introductions are enhancing diagnostic capabilities, catering to the growing need for precision medicine. The market is witnessing a trend towards personalized healthcare, driving the adoption of novel radiotracers. Competition in the PET Radiotracer Market is intense, with key players striving for technological superiority. Benchmarking reveals that companies with robust R&D pipelines and strategic partnerships hold competitive advantages. Regulatory frameworks, particularly in North America and Europe, are pivotal in shaping market dynamics. These regulations ensure safety and efficacy, influencing market entry and expansion strategies. The market is poised for growth, driven by advancements in molecular imaging and an increasing focus on early disease detection. Challenges include regulatory compliance costs and the need for continuous innovation.

Geographical Overview:

The PET radiotracer market is witnessing notable growth across diverse regions, each presenting unique opportunities. North America dominates, driven by advanced healthcare infrastructure and increasing investments in nuclear medicine. The presence of leading pharmaceutical companies also bolsters market expansion. Europe follows, with substantial government funding for research and development in radiopharmaceuticals. The region's focus on precision medicine further propels market growth. In Asia Pacific, the market is burgeoning, supported by rising healthcare expenditures and technological advancements. Countries such as China and India are emerging as key players, investing heavily in healthcare infrastructure and radiotracer research. Latin America and the Middle East & Africa are developing markets with untapped potential. In these regions, increasing awareness of nuclear medicine's benefits is driving demand. Brazil and South Africa are particularly noteworthy, as they enhance their healthcare capabilities and infrastructure. These emerging markets present lucrative opportunities for stakeholders aiming to expand their global footprint in the PET radiotracer sector.

Global tariffs and geopolitical tensions are profoundly influencing the PET Radiotracer Market, particularly in East Asia. Japan and South Korea, traditionally reliant on imported radiotracer materials, are investing in domestic production capabilities to mitigate tariff-induced cost pressures. China, facing export restrictions, is accelerating efforts towards self-sufficiency in radiopharmaceuticals, while Taiwan leverages its advanced manufacturing prowess to bolster its strategic importance amidst regional tensions. The parent market for radiopharmaceuticals is experiencing robust growth globally, driven by advancements in nuclear medicine and rising demand for diagnostic imaging. By 2035, the market is anticipated to evolve with enhanced supply chain resilience and regional collaborations. Meanwhile, Middle East conflicts may indirectly affect energy prices, influencing production costs and logistical frameworks across the region.

Key Trends and Drivers:

The PET Radiotracer Market is experiencing dynamic growth, driven by advancements in medical imaging technologies and increased prevalence of chronic diseases. One key trend is the integration of artificial intelligence in imaging, enhancing diagnostic accuracy and efficiency. This technological evolution is propelling demand as healthcare providers strive for precision medicine. Moreover, there is a growing global focus on early disease detection, particularly in oncology, which is significantly boosting the market. Patients and healthcare systems are increasingly prioritizing early intervention, thus increasing the uptake of PET radiotracers. Another driver is the expanding geriatric population, which is more susceptible to conditions such as cancer and Alzheimer's, further necessitating advanced imaging solutions. Furthermore, partnerships and collaborations among pharmaceutical companies and research institutions are fostering innovation, leading to the development of novel radiotracers. These collaborations are crucial in addressing unmet clinical needs and expanding the application scope of PET radiotracers. Lastly, regulatory support and funding for nuclear medicine research are facilitating market expansion, especially in regions focusing on healthcare infrastructure development.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Component
  • 2.8 Key Market Highlights by Deployment
  • 2.9 Key Market Highlights by Process
  • 2.10 Key Market Highlights by Equipment

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Fluorodeoxyglucose (FDG)
    • 4.1.2 Gallium-68
    • 4.1.3 Carbon-11
    • 4.1.4 Nitrogen-13
    • 4.1.5 Oxygen-15
    • 4.1.6 Copper-64
    • 4.1.7 Zirconium-89
    • 4.1.8 Iodine-124
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Oncology Radiotracers
    • 4.2.2 Cardiology Radiotracers
    • 4.2.3 Neurology Radiotracers
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Radiotracer Production
    • 4.3.2 Radiotracer Distribution
    • 4.3.3 Radiotracer Research and Development
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Cyclotron
    • 4.4.2 Generator-based
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Oncology
    • 4.5.2 Cardiology
    • 4.5.3 Neurology
    • 4.5.4 Infection Imaging
    • 4.5.5 Research
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Hospitals
    • 4.6.2 Diagnostic Centers
    • 4.6.3 Research Institutes
    • 4.6.4 Pharmaceutical Companies
  • 4.7 Market Size & Forecast by Component (2020-2035)
    • 4.7.1 Radioisotopes
    • 4.7.2 Radiopharmaceuticals
  • 4.8 Market Size & Forecast by Deployment (2020-2035)
    • 4.8.1 In-house Production
    • 4.8.2 Outsourced Production
  • 4.9 Market Size & Forecast by Process (2020-2035)
    • 4.9.1 Synthesis
    • 4.9.2 Quality Control
    • 4.9.3 Packaging
    • 4.9.4 Distribution
  • 4.10 Market Size & Forecast by Equipment (2020-2035)
    • 4.10.1 PET Scanners
    • 4.10.2 Cyclotrons
    • 4.10.3 Hot Cells

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Component
      • 5.2.1.8 Deployment
      • 5.2.1.9 Process
      • 5.2.1.10 Equipment
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Component
      • 5.2.2.8 Deployment
      • 5.2.2.9 Process
      • 5.2.2.10 Equipment
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Component
      • 5.2.3.8 Deployment
      • 5.2.3.9 Process
      • 5.2.3.10 Equipment
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Component
      • 5.3.1.8 Deployment
      • 5.3.1.9 Process
      • 5.3.1.10 Equipment
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Component
      • 5.3.2.8 Deployment
      • 5.3.2.9 Process
      • 5.3.2.10 Equipment
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Component
      • 5.3.3.8 Deployment
      • 5.3.3.9 Process
      • 5.3.3.10 Equipment
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Component
      • 5.4.1.8 Deployment
      • 5.4.1.9 Process
      • 5.4.1.10 Equipment
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Component
      • 5.4.2.8 Deployment
      • 5.4.2.9 Process
      • 5.4.2.10 Equipment
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Component
      • 5.4.3.8 Deployment
      • 5.4.3.9 Process
      • 5.4.3.10 Equipment
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Component
      • 5.4.4.8 Deployment
      • 5.4.4.9 Process
      • 5.4.4.10 Equipment
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Component
      • 5.4.5.8 Deployment
      • 5.4.5.9 Process
      • 5.4.5.10 Equipment
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Component
      • 5.4.6.8 Deployment
      • 5.4.6.9 Process
      • 5.4.6.10 Equipment
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Component
      • 5.4.7.8 Deployment
      • 5.4.7.9 Process
      • 5.4.7.10 Equipment
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Component
      • 5.5.1.8 Deployment
      • 5.5.1.9 Process
      • 5.5.1.10 Equipment
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Component
      • 5.5.2.8 Deployment
      • 5.5.2.9 Process
      • 5.5.2.10 Equipment
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Component
      • 5.5.3.8 Deployment
      • 5.5.3.9 Process
      • 5.5.3.10 Equipment
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Component
      • 5.5.4.8 Deployment
      • 5.5.4.9 Process
      • 5.5.4.10 Equipment
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Component
      • 5.5.5.8 Deployment
      • 5.5.5.9 Process
      • 5.5.5.10 Equipment
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Component
      • 5.5.6.8 Deployment
      • 5.5.6.9 Process
      • 5.5.6.10 Equipment
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Component
      • 5.6.1.8 Deployment
      • 5.6.1.9 Process
      • 5.6.1.10 Equipment
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Component
      • 5.6.2.8 Deployment
      • 5.6.2.9 Process
      • 5.6.2.10 Equipment
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Component
      • 5.6.3.8 Deployment
      • 5.6.3.9 Process
      • 5.6.3.10 Equipment
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Component
      • 5.6.4.8 Deployment
      • 5.6.4.9 Process
      • 5.6.4.10 Equipment
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Component
      • 5.6.5.8 Deployment
      • 5.6.5.9 Process
      • 5.6.5.10 Equipment

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Advanced Accelerator Applications
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Blue Earth Diagnostics
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Jubilant Radiopharma
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Curium Pharma
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 SOFIE Biosciences
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 North Star Medical Radioisotopes
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Zevacor Molecular
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 ABX- CRO
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Cyclomedica
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 ITG Isotope Technologies Garching
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Radiopharm Theranostics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 ARTMS Products
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Telix Pharmaceuticals
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Global Medical Solutions
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Imagin Ab
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Eckert & Ziegler Radiopharma
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Shine Medical Technologies
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Lantheus Holdings
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Isotopia Molecular Imaging
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 TRIUMF Innovations
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us